For Alzheimer’s, Detection Advances Outpace Treatment Options
Awilda Jimenez got a scan for Alzheimer’s after she started forgetting
things. It was positive.
By GINA KOLATA Published: November 15, 2012
When Awilda Jimenez started forgetting things last year, her husband,
Edwin, felt a shiver of dread. Her mother had developed Alzheimer’s in her 50s.
Could his wife, 61, have it, too?
He learned there was a new brain scan to diagnose the disease and nervously
agreed to get her one, secretly hoping it would lay his fears to rest. In June,
his wife became what her doctor says is the first private patient in Arizona to
have the test.
“The scan was floridly positive,” said her doctor, Adam S. Fleisher,
director of brain imaging at the Banner Alzheimer’s Institute in Phoenix.
The Jimenezes have struggled ever since to deal with this devastating news.
They are confronting a problem of the new era of Alzheimer’s research: The
ability to detect the disease has leapt far ahead of treatments. There are none
that can stop or even significantly slow the inexorable progression to dementia
and death.
Families like the Jimenezes, with no good options, can only ask: Should
they live their lives differently, get their affairs in order, join a clinical
trial of an experimental drug?
“I was hoping the scan would be negative,” Mr. Jimenez said. “When I found
out it was positive, my heart sank.”
The new brain scan technology, which went on the market in June, is
spreading fast. There are already more than 300 hospitals and imaging centers,
located in most major metropolitan areas, that are ready to perform the scans,
according to Eli Lilly, which sells the tracer used to mark plaque for the scan.
The scans show plaques in the brain — barnaclelike clumps of protein, beta
amyloid — that, together with dementia, are the defining feature of Alzheimer’s
disease. Those who have dementia but do not have excessive plaques do not have
Alzheimer’s. It is no longer necessary to wait until the person dies and has an
autopsy to learn if the brain was studded with plaques.
Many insurers, including Medicare, will not yet pay for the new scans,
which cost several thousand dollars. And getting one comes with serious risks.
While federal law prevents insurers and employers from discriminating based on
genetic tests, it does not apply to scans. People with brain plaques can be
denied long-term care insurance.
The Food and Drug Administration, worried about interpretations of the
scans, has required something new: Doctors must take a test showing they can
read them accurately before they begin doing them. So far, 700 doctors have
qualified, according to Eli Lilly. Other kinds of diagnostic scans have no such
requirement.
In another unusual feature, the F.D.A. requires that radiologists not be
told anything about the patient. They are generally trained to incorporate
clinical information into their interpretation of other types of scans, said Dr.
R. Dwaine Rieves, director of the drug agency’s Division of Medical Imaging
Products.
But in this case, clinical information may lead radiologists to
inadvertently shade their reports to coincide with what doctors suspect is the
underlying disease. With Alzheimer’s, Dr. Rieves said, “clinical impressions
have been misleading.”
“This is a big change in the world of image interpretation,” he said.
Like some other Alzheimer’s experts, Dr. Fleisher used the amyloid scan for
several years as part of a research study that led to its F.D.A. approval.
Subjects were not told what the scans showed. Now, with the scan on the market,
the rules have changed.
Dr. Fleisher’s first patient was Mrs. Jimenez. Her husband, the family
breadwinner, had lost his job as a computer consultant when the couple moved
from New York to Arizona to take care of Mrs. Jimenez’s mother. Paying several
thousand dollars for a scan was out of the question. But Dr. Fleisher found a
radiologist, Dr. Mantej Singh Sra of Sun Radiology, who was so eager to get into
the business that he agreed to do Mrs. Jimenez’s scan free. His plan was to be
the first in Arizona to do a scan, and advertise it.
After Dr. Sra did the scan, the Jimenezes returned to Dr. Fleisher to learn
the result.
Dr. Fleisher, sad to see so much plaque in Mrs. Jimenez’s brain, referred
her to a psychiatrist to help with anxiety and suggested she enter clinical
trials of experimental drugs.
But Mr. Jimenez did not like that idea. He worried about unexpected side
effects.
“Tempting as it is, where do you draw the line?” he asks. “At what point
do you take a risk with a loved one?”
At Mount Sinai Medical Center in New York, Dr. Samuel E. Gandy found that
his patients — mostly affluent — were unfazed by the medical center’s $3,750
price for the scan. He has been ordering at least one a week for people with
symptoms ambiguous enough to suggest the possibility of brain plaques.
Most of his patients want their names kept confidential, fearing an
inability to get long-term care insurance, or just wanting privacy.
(Page 2 of 2)
A woman from New Zealand was told by one doctor that she had Alzheimer’s
and by another that she had frontotemporal dementia, a rare brain disease that
strikes people at younger ages than Alzheimer’s and progresses faster. She had a
scan. The result was clear — no significant accumulation of plaques. She had
frontotemporal dementia. Unfortunately, Dr. Gandy said, there was nothing he
could offer her, not even a clinical drug trial.
A man given a diagnosis of Parkinson’s disease was totally immobile and
demented. Could he have had Alzheimer’s all along?
A scan showed he did.
Dr. Gandy’s first patient, Alexander Dreyfoos, an 80-year-old electronics
engineer and businessman, was one of the very few willing to be open about his
experience. He is independently wealthy and was not worried about privacy or
insurance.
But he was very worried about Alzheimer’s. His mother, who died at age 79,
had it. “I watched her deteriorate to the point where she couldn’t even
recognize me,” Mr. Dreyfoos said. And he had begun seeing signs that his memory
was slipping.
“A few years ago, I realized I wasn’t at the top of my game,” he said.
Mr. Dreyfoos had his DNA sequenced by a commercial company and learned that
he had a gene, ApoE4, that increases the risk of Alzheimer’s. At Massachusetts
General Hospital, he learned he had shrinkage of his brain — typical of
Alzheimer’s. After doctors tested his memory and reasoning, he said, they told
him he was right to worry.
Finally, Mr. Dreyfoos went to Dr. Gandy at Mount Sinai, looking for an
experimental treatment for the Alzheimer’s he was sure he had. Dr. Gandy also
suspected he had the disease, but suggested a scan.
The scan did not show an abnormal accumulation of amyloid. As far as Dr.
Gandy is concerned, Mr. Dreyfoos does not have Alzheimer’s.
Mr. Dreyfoos was surprised, “wonderfully so,” he said.
Dr. Gandy said that as many as 30 percent of people who seem to have
Alzheimer’s turn out not to have it when they get the scan. But those who get
bad news struggle to cope.
Desperate to slow the progression of his wife’s disease, Mr. Jimenez is now
giving her turmeric, coenzyme Q10, astaxanthin, krill oil, ginkgo biloba and
coconut oil — remedies he found on the Internet. There is no good evidence they
work, and each costs about $5 to $15 a month. But, Mr. Jimenez says: “What am I
going to do? People feel so helpless with this disease that they are willing to
try anything.”
He worries about the future and how they will survive financially. He
wonders if it might have been better not to know the diagnosis.
“It is financially, emotionally and spiritually draining,” Mr. Jimenez
said. “Everything hangs by a thread.”
>>> While federal law prevents insurers and employers from
discriminating based on genetic tests, it does not apply to scans.
>>> People with brain plaques can be denied long-term care
insurance.
THIS IS WRONG !
Review
On the issue of transmissibility of Alzheimer disease: A critical review
November/December 2012
Keywords: Alzheimer, dementia, epidemiology, prion, transmissibility
Authors: Christian Schmidt, André Karch, Carsten Korth and Inga Zerr
Christian Schmidt
Corresponding author: schmidt102@gmail.com
Clinical Dementia Center; Department of Neurology; Georg-August University;
Goettingen, Germany
André Karch
Clinical Dementia Center; Department of Neurology; Georg-August University;
Goettingen, Germany
Carsten Korth
Department of Neuropathology; Heinrich-Heine University; Duesseldorf,
Germany
Inga Zerr
Clinical Dementia Center; Department of Neurology; Georg-August University;
Goettingen, Germany
Abstract:
Results from recent experiments with rodents imply that Alzheimer disease
might be inducible by seeding Aβ peptides into recipient animals. In respect to
this new experimental data, public health aspects as well as epidemiological
data have to be reevaluated. In this article, the available experimental and
epidemiological data are reviewed.
snip...
In summary, epidemiological evidence is extremely difficult to assess in
this context. This is especially true, since case definitions and case detection
rates have changed over time. Given the fact that a potential way of
transmission is not only unknown but that no way of transmission can be excluded
yet, careful assessment is imperative.
Public health implications
In the epidemic of non-communicable diseases AD plays an important role for
morbidity and mortality as well as the associated costs. To date, AD is the 6th
leading cause of death in the US and the projected costs in the US by 2050 are
$1.1 trillion.66
Knowledge about transmissibility is essential in all kinds of epidemics for
prevention, diagnosis and treatment. If AD featured transmission patterns
comparable with those of prion diseases, iatrogenic induction/transmission would
play a major role for public health. Prevention would be first priority and
might include measures such as extended sterilization methods for surgical
instruments as well as identification of patients potentially posing a risk as
well as patients at risk. From a public health perspective also alternate ways
of transmission not evaluated yet must be considered. For prevention to work,
biomarkers for early disease detection must be validated, independently of the
ways of possible induction since the disease itself starts well before clinical
onset. As Sigurdsson stated correctly almost 10 years ago, future research on
therapies might also be limited as long as there is no convincing evidence
against transmissibility of AD.8 This is especially true for vaccination studies
and clinical trials using parts of β-amyloid.
Conclusion
In conclusion, with this short review, we want to encourage a broader
discussion and modern epidemiological research in this context. Well-designed
epidemiologic studies have to be initiated. Methodologically these studies must
be constructed to address the epidemiologically challenging aspects of Alzheimer
disease such as dissociation between first neuropathological alterations and
clinical onset, uncertainties in early diagnosis as well as AD heterogeneity.
This work was supported by a Bundesministerium für Bildung und Forschung
grant within the German Network for Degenerative Dementia (KNDD-2, 2012-2015,
determinants for disease progression in AD, grant no. 01GI1010C), as well as
JPND, EU-FP7 PRIORITY.Authors’ contributions: C.S. was responsible for the
initiation of the project, general conception and the composition of the final
manuscript. A.K. provided parts of the section on epidemiology. C.K. provided
parts of the section on experimental clues regarding AD
transmissibility/inducibility. I.Z. was responsible for the initiation of the
project, the critical review for contentual errors and writing parts of the
conclusion. All authors contributed to the revision of the manuscript. The
authors declare no conflicts of interest.
Wednesday, May 16, 2012
Alzheimer’s disease and Transmissible Spongiform Encephalopathy prion
disease, Iatrogenic, what if ?
Proposal ID: 29403
Wednesday, May 16, 2012
Alzheimer’s disease and Transmissible Spongiform Encephalopathy prion
disease, Iatrogenic, what if ?
Proposal ID: 29403
Alzheimer’s disease and Transmissible Spongiform Encephalopathy prion
disease, Iatrogenic, what if ?
Background
Alzheimer’s disease and Transmissible Spongiform Encephalopathy disease
have both been around a long time, and was discovered in or around the same time
frame, early 1900’s. Both disease, and it’s variants, in many cases are merely
names of the people that first discovered them. Both diseases are incurable and
debilitating brain disease, that are in the end, 100% fatal, with the
incubation/clinical period of the Alzheimer’s disease being longer than the TSE
prion disease. Symptoms are very similar, and pathology is very similar. I
propose that Alzheimer’s is a TSE disease of low dose, slow, and long incubation
disease, and that Alzheimer’s is Transmissible, and is a threat to the public
via the many Iatrogenic routes and sources. It was said long ago that the only
thing that disputes this, is Alzheimer’s disease transmissibility, or the lack
of. today, there is enough documented science (some confidential), that shows
that indeed Alzheimer’s is transmissible. The risk factor for friendly fire, and
or the pass-it-forward mode i.e. Iatrogenic transmission is a real threat, and
one that needs to be addressed immediately.
Methods
Through years of research, as a layperson, of peer review journals,
transmission studies, and observations of loved ones and friends that have died
from both Alzheimer’s and the TSE prion disease i.e. Heidenhain Variant
Creutzfelt Jakob Disease CJD.
Results
The likelihood of many victims of Alzheimer’s disease from the many
different Iatrogenic routes and modes of transmission as with the TSE prion
disease. TSE prion disease survives ashing to 600 degrees celsius, that’s around
1112 degrees farenheit. you cannot cook the TSE prion disease out of meat. you
can take the ash and mix it with saline and inject that ash into a mouse, and
the mouse will go down with TSE. Prion Infected Meat-and-Bone Meal Is Still
Infectious after Biodiesel Production as well. the TSE prion agent also survives
Simulated Wastewater Treatment Processes. IN fact, you should also know that the
TSE Prion agent will survive in the environment for years, if not decades. you
can bury it and it will not go away. TSE prion agent is capable of infected your
water table i.e. Detection of protease-resistant cervid prion protein in water
from a CWD-endemic area. it’s not your ordinary pathogen you can just cook it
out and be done with. that’s what’s so worrisome about Iatrogenic mode of
transmission, a simple autoclave will not kill this TSE prion agent.
Conclusions
There should be a Global Congressional Science round table event (one of
scientist and doctors et al only, NO CORPORATE, POLITICIANS ALLOWED) set up
immediately to address these concerns from the many potential routes and sources
of the TSE prion disease, including Alzheimer’s disease, and a emergency global
doctrine put into effect to help combat the spread of Alzheimer’s disease via
the medical, surgical, dental, tissue, and blood arena’s. All human and animal
TSE prion disease, including Alzheimer’s should be made reportable in every
state, and Internationally, WITH NO age restrictions. Until a proven method of
decontamination and autoclaving is proven, and put forth in use universally, in
all hospitals and medical, surgical arena’s, or the TSE prion agent will
continue to spread. IF we wait until science and corporate politicians wait
until politics let science _prove_ this once and for all, and set forth
regulations there from, we will all be exposed to the TSE Prion agents, if that
has not happened already. what’s the use of science progressing human life to
the century mark, if your brain does not work?
combined cannot exceed 350 Words
shortened to proper word count ;
Alzheimer’s disease and Transmissible Spongiform Encephalopathy prion
disease, Iatrogenic, what if ?
Background
Alzheimer’s disease and Transmissible Spongiform Encephalopathy disease
have both been around a long time, and was discovered in or around the same time
frame, early 1900’s. Both diseases are incurable and debilitating brain disease,
that are in the end, 100% fatal, with the incubation/clinical period of the
Alzheimer’s disease being longer (most of the time) than the TSE prion disease.
Symptoms are very similar, and pathology is very similar.
Methods
Through years of research, as a layperson, of peer review journals,
transmission studies, and observations of loved ones and friends that have died
from both Alzheimer’s and the TSE prion disease i.e. Heidenhain Variant
Creutzfelt Jakob Disease CJD.
Results
I propose that Alzheimer’s is a TSE disease of low dose, slow, and long
incubation disease, and that Alzheimer’s is Transmissible, and is a threat to
the public via the many Iatrogenic routes and sources. It was said long ago that
the only thing that disputes this, is Alzheimer’s disease transmissibility, or
the lack of. The likelihood of many victims of Alzheimer’s disease from the many
different Iatrogenic routes and modes of transmission as with the TSE prion
disease.
Conclusions
There should be a Global Congressional Science round table event set up
immediately to address these concerns from the many potential routes and sources
of the TSE prion disease, including Alzheimer’s disease, and a emergency global
doctrine put into effect to help combat the spread of Alzheimer’s disease via
the medical, surgical, dental, tissue, and blood arena’s. All human and animal
TSE prion disease, including Alzheimer’s should be made reportable in every
state, and Internationally, WITH NO age restrictions. Until a proven method of
decontamination and autoclaving is proven, and put forth in use universally, in
all hospitals and medical, surgical arena’s, or the TSE prion agent will
continue to spread. IF we wait until science and corporate politicians wait
until politics lets science _prove_ this once and for all, and set forth
regulations there from, we will all be exposed to the TSE Prion agents, if that
has not happened already.
end...tss
Alzheimer’s disease and Transmissible Spongiform Encephalopathy prion
disease, Iatrogenic, what if ?
source references
Ann N Y Acad Sci. 1982;396:131-43.
Alzheimer's disease and transmissible virus dementia (Creutzfeldt-Jakob
disease).
Brown P, Salazar AM, Gibbs CJ Jr, Gajdusek DC.
Abstract
Ample justification exists on clinical, pathologic, and biologic grounds
for considering a similar pathogenesis for AD and the spongiform virus
encephalopathies. However, the crux of the comparison rests squarely on results
of attempts to transmit AD to experimental animals, and these results have not
as yet validated a common etiology. Investigations of the biologic similarities
between AD and the spongiform virus encephalopathies proceed in several
laboratories, and our own observation of inoculated animals will be continued in
the hope that incubation periods for AD may be even longer than those of CJD.
BSE101/1 0136
IN CONFIDENCE
CMO
From: Dr J S Metters DCMO
4 November 1992
TRANSMISSION OF ALZHEIMER TYPE PLAQUES TO PRIMATES
CJD1/9 0185
Ref: 1M51A
IN STRICT CONFIDENCE
From: Dr. A Wight Date: 5 January 1993
Copies:
Dr Metters
Dr Skinner
Dr Pickles
Dr Morris
Mr Murray
TRANSMISSION OF ALZHEIMER-TYPE PLAQUES TO PRIMATES
Wednesday, January 5, 2011
ENLARGING SPECTRUM OF PRION-LIKE DISEASES Prusiner Colby et al 2011 Prions
David W. Colby1,* and Stanley B. Prusiner1,2
Tuesday, October 4, 2011
Molecular Psychiatry
advance online publication 4 October 2011; doi: 10.1038/mp.2011.120
De novo induction of amyloid-ß deposition in vivo
Our results suggest that some of the typical brain abnormalities associated
with AD can be induced by a prion-like mechanism of disease transmission through
propagation of protein misfolding. These findings may have broad implications
for understanding the molecular mechanisms responsible for the initiation of AD,
and may contribute to the development of new strategies for disease prevention
and intervention. Keywords: amyloid; prion; protein misfolding; disease
transmission
see more here ;
Wednesday, September 21, 2011
PrioNet Canada researchers in Vancouver confirm prion-like properties in
Amyotrophic Lateral Sclerosis (ALS)
snip...end
Thank You for accepting my submission
# 29403, Alzheimer’s disease and Transmissible Spongiform Encephalopathy
prion disease, Iatrogenic, what if ? and the opportunity to present it, at the
Alzheimer’s Association International Conference 2012 (AAIC), as a poster
presentation. However, with great sadness, I must regretfully decline the
invitation due to a medical reasons, and traveling to Canada, of which is not
possible. ...
Thank You,
With Kindest Regards,
I am sincerely,
Terry S. Singeltary Sr.
P.O. Box 42
Bacliff, Texas USA 77518
From:
Sent: Saturday, April 07, 2012 8:20 PM
To: Terry S. Singeltary Sr.
Subject: RE: re-submission
Dear Terry,
Yes, your proposal was accepted as a poster presentation. Please decline
the invitation if appropriate.
Best Regards,
______________________________________
Alzheimer’s Association – National Office
225 North Michigan Avenue – Floor 17
Chicago, Illinois 60601
=============snip...end...source reference...# 29403==========
TSS
UPDATE JUNE 28, 2012
Scottish TSE Network November Symposium Announcement Event: 12 November
2012
Chair: Prof Hugh Perry, University of Southampton, Southampton UK
Location: The Roslin Institute Building Auditorium
If you would like to book a place at this event, please let Gila Holliman
know.
Cost: £125.
Title: Is Alzheimer’s Disease a transmissible disease?
Speakers:
Session 1:
Prof Bob Will, National CJD Surveillance Unit, Edinburgh UK
Prof James Ironside, National CJD Surveillance Unit, Edinburgh UK
Prof Lary Walker, Emory School of Medicine, Atlanta USA
Session 2:
Prof Mathias Jucker, Hertie Institute for Clinical Brain Research,
Stuttgart Germany
Prof William Van Nostrand, Stony Brook University, Stony Brook USA
Dr Claudio Soto, University of Texas Medical School, Houston USA
Session 3:
Dr Fabrizio Tagliavini, Instituto Neurologico Carlo Besta, Milan Italy
Prof Pedro Piccardo, Food and Drug Administration, Washington DC USA
Dr Bruce Chesebro, National Institutes of Health, Missoula USA
see ;
Wednesday, May 16, 2012
Alzheimer’s disease and Transmissible Spongiform Encephalopathy prion
disease, Iatrogenic, what if ?
Proposal ID: 29403
14th ICID International Scientific Exchange Brochure -
Final Abstract Number: ISE.114
Session: International Scientific Exchange
Transmissible Spongiform encephalopathy (TSE) animal and human TSE in North
America update October 2009
T. Singeltary
Bacliff, TX, USA
Background:
An update on atypical BSE and other TSE in North America. Please remember,
the typical U.K. c-BSE, the atypical l-BSE (BASE), and h-BSE have all been
documented in North America, along with the typical scrapie's, and atypical
Nor-98 Scrapie, and to date, 2 different strains of CWD, and also TME. All these
TSE in different species have been rendered and fed to food producing animals
for humans and animals in North America (TSE in cats and dogs ?), and that the
trading of these TSEs via animals and products via the USA and Canada has been
immense over the years, decades.
Methods:
12 years independent research of available data
Results:
I propose that the current diagnostic criteria for human TSEs only enhances
and helps the spreading of human TSE from the continued belief of the UKBSEnvCJD
only theory in 2009. With all the science to date refuting it, to continue to
validate this old myth, will only spread this TSE agent through a multitude of
potential routes and sources i.e. consumption, medical i.e., surgical, blood,
dental, endoscopy, optical, nutritional supplements, cosmetics etc.
Conclusion:
I would like to submit a review of past CJD surveillance in the USA, and
the urgent need to make all human TSE in the USA a reportable disease, in every
state, of every age group, and to make this mandatory immediately without
further delay. The ramifications of not doing so will only allow this agent to
spread further in the medical, dental, surgical arena's. Restricting the
reporting of CJD and or any human TSE is NOT scientific. Iatrogenic CJD knows NO
age group, TSE knows no boundaries. I propose as with Aguzzi, Asante, Collinge,
Caughey, Deslys, Dormont, Gibbs, Gajdusek, Ironside, Manuelidis, Marsh, et al
and many more, that the world of TSE Transmissible Spongiform Encephalopathy is
far from an exact science, but there is enough proven science to date that this
myth should be put to rest once and for all, and that we move forward with a new
classification for human and animal TSE that would properly identify the
infected species, the source species, and then the route.
Friday, October 05, 2012
Differential Diagnosis of Jakob-Creutzfeldt Disease
Monday, August 20, 2012
CASE REPORTS CREUTZFELDT-JAKOB DISEASE: AN UNDER-RECOGNIZED CAUSE OF
DEMENTIA
see the Duke, Pa, Yale, and Mexican study here, showing the misdiagnosis of
CJD TSE prion disease as Alzheimers ;
Terry S. Singeltary Sr. on the Creutzfeldt-Jakob Disease Public Health
Crisis
full text with source references ;
re-Human Prion Diseases in the United States Posted by flounder on 01 Jan
2010 at 18:11 GMT
I kindly disagree with your synopsis for the following reasons ;
Tuesday, November 08, 2011
Can Mortality Data Provide Reliable Indicators for Creutzfeldt-Jakob
Disease Surveillance? A Study in France from 2000 to 2008 Vol. 37, No. 3-4, 2011
Original Paper
Conclusions:These findings raise doubt about the possibility of a reliable
CJD surveillance only based on mortality data.
Views & Reviews
Monitoring the occurrence of emerging forms of Creutzfeldt-Jakob disease in
the United States
Ermias D. Belay, MD, Ryan A. Maddox, MPH, Pierluigi Gambetti, MD and
Lawrence B. Schonberger, MD
+ Author Affiliations
From the Division of Viral and Rickettsial Diseases (Drs. Belay and
Schonberger and R.A. Maddox), National Center for Infectious Diseases, Centers
for Disease Control and Prevention, Atlanta, GA; and National Prion Disease
Pathology Surveillance Center (Dr. Gambetti), Division of Neuropathology,
Institute of Pathology, Case Western Reserve University, Cleveland, OH.
Address correspondence and reprint requests to Dr. Ermias D. Belay, 1600
Clifton Road, Mailstop A-39, Atlanta, GA 30333.
26 March 2003
Terry S. Singeltary, retired (medically) CJD WATCH
I lost my mother to hvCJD (Heidenhain Variant CJD). I would like to comment
on the CDC's attempts to monitor the occurrence of emerging forms of CJD.
Asante, Collinge et al [1] have reported that BSE transmission to the
129-methionine genotype can lead to an alternate phenotype that is
indistinguishable from type 2 PrPSc, the commonest sporadic CJD. However, CJD
and all human TSEs are not reportable nationally. CJD and all human TSEs must be
made reportable in every state and internationally. I hope that the CDC does not
continue to expect us to still believe that the 85%+ of all CJD cases which are
sporadic are all spontaneous, without route/source. We have many TSEs in the USA
in both animal and man. CWD in deer/elk is spreading rapidly and CWD does
transmit to mink, ferret, cattle, and squirrel monkey by intracerebral
inoculation. With the known incubation periods in other TSEs, oral transmission
studies of CWD may take much longer. Every victim/family of CJD/TSEs should be
asked about route and source of this agent. To prolong this will only spread the
agent and needlessly expose others. In light of the findings of Asante and
Collinge et al, there should be drastic measures to safeguard the medical and
surgical arena from sporadic CJDs and all human TSEs. I only ponder how many
sporadic CJDs in the USA are type 2 PrPSc?
Diagnosis and Reporting of Creutzfeldt-Jakob Disease Singeltary, Sr et al.
JAMA.2001; 285: 733-734. Vol. 285 No. 6, February 14, 2001 JAMA
Diagnosis and Reporting of Creutzfeldt-Jakob Disease
To the Editor: In their Research Letter, Dr Gibbons and colleagues1
reported that the annual US death rate due to Creutzfeldt-Jakob disease (CJD)
has been stable since 1985. These estimates, however, are based only on reported
cases, and do not include misdiagnosed or preclinical cases. It seems to me that
misdiagnosis alone would drastically change these figures. An unknown number of
persons with a diagnosis of Alzheimer disease in fact may have CJD, although
only a small number of these patients receive the postmortem examination
necessary to make this diagnosis. Furthermore, only a few states have made CJD
reportable. Human and animal transmissible spongiform encephalopathies should be
reportable nationwide and internationally.
Terry S. Singeltary, Sr Bacliff, Tex
1. Gibbons RV, Holman RC, Belay ED, Schonberger LB. Creutzfeldt-Jakob
disease in the United States: 1979-1998. JAMA. 2000;284:2322-2323. FREE FULL
TEXT
The Lancet Infectious Diseases, Volume 3, Issue 8, Page 463, August 2003
doi:10.1016/S1473-3099(03)00715-1Cite or Link Using DOI
Tracking spongiform encephalopathies in North America
Original
Xavier Bosch
“My name is Terry S Singeltary Sr, and I live in Bacliff, Texas. I lost my
mom to hvCJD (Heidenhain variant CJD) and have been searching for answers ever
since. What I have found is that we have not been told the truth. CWD in deer
and elk is a small portion of a much bigger problem.” 49-year—old Singeltary is
one of a number of people who have remained largely unsatisfied after being told
that a close relative died from a rapidly progressive dementia compatible with
spontaneous Creutzfeldt—Jakob ...
2 January 2000
British Medical Journal
U.S. Scientist should be concerned with a CJD epidemic in the U.S., as well
15 November 1999
British Medical Journal
vCJD in the USA * BSE in U.S.
Saturday, January 2, 2010
Human Prion Diseases in the United States January 1, 2010 ***FINAL***
Monday, March 29, 2010
CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN
AND SPINAL CORD MATTER URGENT, PLEASE NOTE ;
>>> Up until about 6 years ago, the pt worked at Tyson foods where
she worked on the assembly line, slaughtering cattle and preparing them for
packaging. She was exposed to brain and spinal cord matter when she would
euthanize the cattle. <<<
Irma Linda Andablo CJD Victim, she died at 38 years old on February 6, 2010
in Mesquite Texas.
She left 6 Kids and a Husband.The Purpose of this web is to give
information in Spanish to the Hispanic community, and to all the community who
want's information about this terrible disease.- Physician Discharge Summary,
Parkland Hospital, Dallas Texas Admit Date: 12/29/2009 Discharge Date: 1/20/2010
Attending Provider: Greenberg, Benjamin Morris; General Neurology Team: General
Neurology Team Linda was a Hispanic female with no past medical history presents
with 14 months of incresing/progressive altered mental status, generalized
weakness, inability to walk, loss of appetite, inability to speak, tremor and
bowel/blader incontinence. She was, in her usual state of health up until
February, 2009, when her husbans notes that she began forgetting things like
names and short term memories. He also noticed mild/vague personality changes
such as increased aggression. In March, she was involved in a hit and run
MVA,although she was not injured. The police tracked her down and ticketed her.
At that time, her son deployed to Iraq with the Army and her husband assumed her
mentation changes were due to stress over these two events. Also in March, she
began to have weakness in her legs, making it difficult to walk. Over the next
few months, her mentation and personality changes worsened, getting to a point
where she could no longer recognized her children. She was eating less and less.
She was losing more weight. In the last 2-3 months, she reached the point where
she could not walk without an assist, then 1 month ago, she stopped talking,
only making grunting/aggressive sounds when anyone came near her. She also
became both bowel and bladder incontinent, having to wear diapers. Her
'"tremor'" and body jerks worsened and her hands assumed a sort of permanent
grip position, leading her family to put tennis balls in her hands to protect
her fingers. The husband says that they have lived in Nebraska for the past 21
years. They had seen a doctor there during the summer time who prescribed her
Seroquel and Lexapro, Thinking these were sx of a mood disorder. However, the
medications did not help and she continued to deteriorate clinically. Up until
about 6 years ago, the pt worked at Tyson foods where she worked on the assembly
line, slaughtering cattle and preparing them for packaging. She was exposed to
brain and spinal cord matter when she would euthanize the cattle. The husband
says that he does not know any fellow workers with a similar illness. He also
says that she did not have any preceeding illness or travel.
Friday, August 24, 2012
Iatrogenic prion diseases in humans: an update
Thursday, April 12, 2012
Health professions and risk of sporadic Creutzfeldt–Jakob disease, 1965 to
2010
Eurosurveillance, Volume 17, Issue 15, 12 April 2012
Research articles
snip...
In 2009, a pathologist with sporadic Creutzfeldt–Jakob Disease (sCJD) was
reported to the Spanish registry. This case prompted a request for information
on health-related occupation in sCJD cases from countries participating in the
European Creutzfeldt Jakob Disease Surveillance network (EuroCJD). Responses
from registries in 21 countries revealed that of 8,321 registered cases, 65
physicians or dentists, two of whom were pathologists, and another 137
healthcare workers had been identified with sCJD. Five countries reported 15
physicians and 68 other health professionals among 2,968 controls or non-cases,
suggesting no relative excess of sCJD among healthcare professionals. A
literature review revealed: (i) 12 case or small case-series reports of 66
health professionals with sCJD, and (ii) five analytical studies on
health-related occupation and sCJD, where statistically significant findings
were solely observed for persons working at physicians' offices (odds ratio: 4.6
(95 CI: 1.2–17.6)). We conclude that a wide spectrum of medical specialities and
health professions are represented in sCJD cases and that the data analysed do
not support any overall increased occupational risk for health professionals.
Nevertheless, there may be a specific risk in some professions associated with
direct contact with high human-infectivity tissue.
snip...
Friday, August 10, 2012
Incidents of Potential iatrogenic Creutzfeldt-Jakob disease (CJD) biannual
update (July 2012)
Wednesday, January 5, 2011
ENLARGING SPECTRUM OF PRION-LIKE DISEASES Prusiner Colby et al 2011
Prions
David W. Colby1,* and Stanley B. Prusiner1,2
Monday, March 26, 2012
CANINE SPONGIFORM ENCEPHALOPATHY: A NEW FORM OF ANIMAL PRION DISEASE
OR-09 15:10 - 15:25
CANINE SPONGIFORM ENCEPHALOPATHY: A NEW FORM OF ANIMAL PRION DISEASE
======================
*** Saturday, October 6, 2012
*** TRANSMISSION, DIFFERENTIATION, AND PATHOBIOLOGY OF TRANSMISSIBLE
SPONGIFORM ENCEPHALOPATHIES 2011 Annual Report
======================
MOM DOD 12/14/97 hvCJD confirmed, Uncle Bo DOD today 10/13/12 RIP with
severe and rapid last two weeks Alzheimer’s, he was fishing off pier two weeks
ago, hospice 3 days ago, to DOD TODAY (no brain autopsy)?, Mema passed with
moderate to slow dementia type Alzheimer’s, wonder what kind of dementia I will
get ?
======================
Saturday, October 13, 2012
On the issue of transmissibility of Alzheimer disease: A critical review
Subject: Lord Lucas asked Her Majesty's Government about insurance company's and CJD???
Date: Thu, 6 Apr 2000 09:49:14 -0700
From: "Terry S. Singeltary Sr."
Reply-To: Bovine Spongiform Encephalopathy
To: BSE-L@uni-karlsruhe.de
######### Bovine Spongiform Encephalopathy
Greetings Everyone,
I am deeply concerned about the answer given to Lord Lucas on CJD and
insurance company's. In Her Majesty's reply, the reason given for
insurance company's _not_ being able to require candidates for life
insurance to be tested for incipient nvCJD or any human TSE, was because there is no test to date, that would allow them to test.
My question to Her Majesty's Court would have been;
when such a test is available, will the insurance company's be allowed
to test for human TSE's?
It seems Lord Lucas question was not answered fully, it seems Her
Majesty's Court just went around the question.
If in fact, the insurance company's are allowed to do this, once again
the people would have been deceived by their government, for the sake
of money, greed, and corporate industry$$$ This would be devastating
to the people, not only have they been murdered by corporate greed,
but they then would be sold out, for corporate greed. It's a no-win
situation for public consumers...
kind regards,
Terry S. Singeltary Sr., Bacliff, Texas USA
April 4, 2000
Lord Lucas asked Her Majesty's Government:
Whether they will permit insurance companies to require that candidates for life insurance be tested for incipient
new-variant CJD.[HL1661]
Lord Hunt of Kings Heath: Insurance companies would be unable to
introduce such a step, as no acceptable test currently exists for the demonstration of infection before the onset of clinical
symptoms.
Subject: Re: re-Lord Lucas U.K. Government sells out CJD victims (and others)'again' / U.K. Government O.K.'s Genetic testing for Insurers, looking for hereditary illnesses
Date: Fri, 13 Oct 2000 09:37:22 -0700
From: "Terry S. Singeltary Sr."
######### Bovine Spongiform Encephalopathy
first Huntington's, then CJD, then another, and so on.
what needs to take place, is everyone drop their insurance.
once you give these people an opening, it's like a hole in
a dam, there is no closing it, and it just gets bigger and
bigger. This is a serious breach of human ethics, all for the
almighty dollar$$$
kind regards,
Terry
DEPARTMENT OF HEALTH 2000/0580 Friday 13th October 2000 COMMITTEE ANNOUNCES DECISION ON USE OF GENETIC TEST
RESULTS FOR HUNTINGTON'S DISEASE BY INSURERS
The Genetics and Insurance Committee (GAIC) has today announced that
the reliability and relevance of the genetic test for Huntington's
Disease is sufficient for insurance companies to use the result when
assessing applications for life insurance.
Professor John Durant, Chairman of GAIC said:
"Genetic test results are already used in certain circumstances by
insurers and the Committee was asked to look at the reliability and
accuracy of the genetic test for Huntington's Disease. We have
considered carefully the application received from the Association of
British Insurers for approval of the use of these tests. The evidence presented demonstrates that the two tests for the
Huntington's gene are reliable and that an abnormal result is
associated with significant clinical effects and with an increased
probability of a claim on a life insurance policy. This decision
will mean that those with a negative test result will not be asked to
pay more for life insurance because of their family history of
HuntingtonÆs disease.
"This decision does not mean that individuals will be asked to have a
genetic test for Huntington's Disease before obtaining insurance but,
where individuals have already been tested as part of their medical
care, then there is nothing to prevent insurance companies asking for
that information.
"Many who have a family history of a genetic disorder such as
Huntington's Disease have difficulty in obtaining insurance because
of their family history. The approval of the two tests for
Huntington's Disease will allow insurance to be provided at normal
rates to those who have a normal test result."
A significant amount of data has been collected concerning the
effects of Huntington's Disease on life expectancy and on mortality
risk as part of the process of reviewing this application. The
Committee hopes that the insurance industry will use this information
to look at the problems of those who have an abnormal genetic test
result and of those who have chosen not to have a genetic test (who
have a 50 % chance of carrying the abnormal gene if they have an
affected parent).
The GAIC was asked to examine the actuarial evidence for using
individual genetic tests. The insurance industry, through the main
trade body the Association of British Insurers, has agreed to abide
by GAIC decisions. If GAIC decides that the evidence on the
reliability and relevance of a particular test is insufficient to
justify its use, the Association have agreed to stop using them and
retrospectively reassess affected individual insurance premiums. The
broader social and ethical issues surrounding the use of genetic
tests in insurance and employment have been referred to the new Human
Genetics Commission.
An application for approval of two genetic tests for Huntington's
Disease was submitted to GAIC by the Association of British Insurers
(ABI) in July 2000. The application was sent to a clinical
geneticist and an independent actuary for expert review and also to
support groups for Huntington's Disease and to the Genetic Interest
Group (GIG) for their comments. At their meeting on 28 September,
GAIC considered the application, in the presence of observers from
the ABI, GIG and Huntington's Disease Association. Their decision is
announced today.
The committee recognises that this complex subject is an important
issue to the public, industry and government alike. GAIC will work
closely with the new Human Genetics Commission when they begin their
inquiry into the use of genetic data including in insurance and
employment later this year.
Notes to Editors: A summary of the decision and further details about GAIC and the
application process are available on the Department of Health web
site at www.doh.gov.uk/genetics/gaic.htm
The establishment of the Genetics and Insurance Committee (GAIC) on
12 April 1999 fulfilled the Government's commitment to establish an
independent review body, to evaluate the scientific and actuarial
evidence presented in support of the use of specific genetic tests
for insurance products. This was made in response to the Human
Genetics Advisory Commission (HGAC) report on the Implications of
Genetic Testing for the Insurance Industry, issued in December 1998.
GAIC is a non-statutory Advisory Committee and has a UK-wide remit.
Its terms of reference are:
- to develop and publish criteria for the evaluation of specific
genetic tests, their application to particular conditions and their
reliability and relevance to particular types of insurance; - to evaluate
particular tests against those criteria and promulgate
its findings;
- to report to Health, Treasury and Department of Trade and Industry
Ministers on proposals received by GAIC from insurance providers and
the subsequent level of compliance by the industry with the
recommendations of GAIC.
The core membership of GAIC is: Professor John Durant, Chief Executive of At-Bristol as Chairman, appointed from amongst the members of Advisory Committee on Genetic Testing;
Professor Sandy Raeburn, a geneticist nominated by the Association of
British Insurers (ABI);
Professor Dian Donnai a geneticist nominated by CMO (England); Dr David Muiry, an Actuary nominated by the Faculty and Institute of
Actuaries;
Mr Anthony OÆLeary, an Insurance Practitioner nominated by the ABI; Mrs Susan Watkin and Mrs Barbara Carmichael, members of Patient
Support Organisations nominated by the Genetic Interest Group; Professor Tim Bishop, an academic with a background in epidemiology
and genetics nominated by the Director of Research, Department of
Health.
GAIC has published evaluation criteria covering the details of the
genetic condition being tested for, the accuracy and reliability of
the tests used to detect it and the relevance of the test results to
decisions about insurance underwriting. GAIC expects that
applications will be for genetic conditions caused by changes in a
single gene, that are very likely to lead to serious ill health or
disability and that are therefore most relevant to the setting of
premiums for life and health insurance.
Over the next few months, GAIC will consider applications relating to
the conditions currently covered by the Association for British
Insurers' Code of Practice on Genetic Testing. These include
Huntington's Disease, myotonic dystrophy, the early-onset form of
Alzheimer's disease and rare inherited cancers. The intention is to
complete review these applications by June 2001.
The Human Genetics Commission, chaired by Baroness Helena Kennedy,
was created in 1999 to provide the Government with strategic advice
on the wider implications of human genetics. It replaces three former
committees and is responsible for making links between all the other
relevant bodies in the advisory and regulatory framework. Further
information can be found at www.hgc.gov.uk
HGC has been formulating a public consultation exercise on the
storage, protection and use of personal genetic information which
will include the use of genetic data for insurance purposes. The
issues are due to be discussed at a public consultative meeting at
the Centre for Life, Newcastle-upon-Tyne in November 2000.
"Terry S. Singeltary Sr." wrote:
>
> ######### Bovine Spongiform Encephalopathy
>
> Greetings List,
>
> Talk about something that really stinks, this does. First
> the U.K. Government allows the Industry's involved to continue
> to murder (God only knows how many). Then they don't support them,
> and to top it off, they then allow the only hope one has to
> get any kind of medical care, they allow the insurers to bail
> out on victims of this man-made blunder. I thought Lord Lucas
> asked this question to Her Majesty's Court, and Her Majesty's
> Court said;
>
> ######### Bovine Spongiform Encephalopathy
> #########
>
> They replied that as there was no test they could not test, so the
> question did not arise!
>
> Ralph
>
> > Did I miss something or have they not yet responded to this one?
> >
> > Question 20: Whether they will permit insurance companies to require > that
> > customers be tested for incipient nvCJD.
>
> Dear Lord Lucas,
>
> the question has arised again, and should be confronted.
> may i suggest that you ask this question again. it would seem,
> with a test so close to come about for the testing of TSE's,
> one would think, they are just preparing for the worse, and
> covering their butts, at the same time.
>
> Politics as usual, but my God, have not these people suffered
> enough, without the Governments completely stripping them
> from any help at all. Hell, you should just take them out back
> and shoot them........
>
> kind regards,
> Terry S. Singeltary Sr., Bacliff, Texas USA
> ===========================================
>
> Thursday, 12 October, 2000, 11:28 GMT 12:28
> UK Genetic test first for UK
>
> Genetic tests can predict future illness
> Insurers in the UK are to be allowed to use
> genetic test results to identify people with
> hereditary illnesses.
>
> The government will announce on Friday that
> insurers will be able to use those results to
> refuse cover or to push up premiums for those
> born with genes that could lead to fatal
> conditions.
>
> The decision makes Britain the first country to
> approve the commercial use of gene
> technology in this way.
>
> The Genetics and
> Insurance Committee,
> an advisory body
> reporting to the
> Department of Health,
> has decided that a test
> used to identify a
> hereditary risk of
> contracting the disease
> Huntington's chorea is
> technically reliable.
>
> Tests covering several other conditions,
> including hereditary breast cancer and
> Alzheimer's disease, are also awaiting approval.
>
> Two years ago another advisory body, the
> Human Genetics Advisory Commission,
> recommended a moratorium on the use of
> information from such tests.
>
> However, that advice was rejected by the
> government, which decided insurers should be
> able to use such information, subject to the
> Genetics and Insurance Committee agreeing a
> test's technical reliability.
>
> The announcement is likely to fuel the ethical
> debate over the use of genetic information.
>
> Critics fear that vulnerable groups could find it
> difficult to get a mortgage or life insurance, or
> face higher premiums.
>
> But the insurance industry dismissed that
> suggestion.
>
> No compulsion
>
> Professor John Durant, chairman of the
> Genetics and Insurance Committee, told the
> BBC that nobody would be asked to take a
> genetic test by an insurance company.
>
> Rather they would be
> expected to disclose
> the results of any
> genetic test for
> Huntington's disease
> they had taken in the
> past.
>
> Professor Durant said
> this would not be a
> legal obligation, but
> insurance companies
> would have the right to
> refuse to offer
> insurance if a customer
> refused to reveal details.
>
> He said: "It is not a punitive step. This will
> actually benefit very many people seeking
> insurance.
>
> "The only people who are likely to have taken
> a test for Huntington's disease are people with
> a family history of this disease.
>
> "Many of those people will actually have had
> results which show that they are fortunate
> enough not to have inherited the gene, so
> those people will be able to get insurance, at
> the moment they may well find it difficult."
>
> Mary Francis, the Director-General of the
> Association of British Insurers, said that
> companies already asked potential customers
> about family history of disease.
>
> She said: "This is really an extension of what
> already does happen."
>
> Sue Watkin, chair of
> the Huntington's
> Disease Association,
> also said insurance
> companies were already
> using genetic test
> results to calculate or
> refuse premiums.
>
> She said: "Our main concern is that people at
> risk of late onset genetic disorders should be
> able to get insurance of some kind up to a
> certain level.
>
> "At present, many people are made offers they
> just cannot afford."
>
> Ms Watkin said that a person at 50% risk of
> developing Huntington's often found their
> insurance premium loaded by as much as
> 300%.
>
> She called on the government to establish a
> fund to be used to provide insurance for
> people at risk.
>
> The National Consumers' Council is concerned
> people will be put off having tests because
> they feared that the results might count
> against them - with a possible knock-on effect
> on their health.
>
> A spokeswoman said: "A person might think if I
> take a test I will know information that I don't
> know now, and maybe ignorance is bliss.
>
> "If you don't know the information you can't
> put it on the form."
>
> The Human Genetics Commission, another
> government advisory body overseeing
> developments in the use of genetic
> technology, said that it would launch shortly a
> major public consultation exercise about the
> use and protection of genetic information,
> which would include insurance issues.
>
> The exercise would eventually result in the
> Commission making recommendations to
> ministers.
>
> http://news.bbc.co.uk/hi/english/health/newsid_968000/968443.stm
>
END...TSS
Subject: Re: CJD $ BLOOD $ Schmerr test$$$
Date: Wed, 18 Oct 2000 11:01:01 -0700
From: "Terry S. Singeltary Sr."
Reply-To: Bovine Spongiform Encephalopathy
To: BSE-L@uni-karlsruhe.de
References: 1
######### Bovine Spongiform Encephalopathy
Greetings again List Members,
it just hit me about the blood testing. bought knocked me out of the
chair. could it be, the reason they have stalled the blood testing, they
are waiting for the genetic testing to be perfected for the insurance
company's. once perfected and implemented, and no risk of any type
medical insurance coverage for TSE patients, then they will be allowed
to go ahead with the blood tests for human TSE's. pretty smart huh, they
don't pay all these Gov. Officials just to cram BSE tainted hamburgers
down the throat of their daughters, or just for nothing. They pay a good
portion of them to think up schemes, to get them out of man-made
environmental death sentences. I would love to know, who thought
up the scheme, to brain-wash everyone into believing the 'CHOSEN ONES'
are the only ones tied to this man-made death sentence? Probably the
same one to think up the genetic testing for insurance companies.
Oh, well, this pretty much does it for me today. Probably already
over-loaded myself today. Now i know why Mr. Schmitt only allows 4
messages.
kind regards,
Terry S. Singeltary Sr., Bacliff, Texas USA
Department of Health Statement - Genetic Testing and Insurance
http://213.38.88.195/coi/coipress.nsf/70e1fa6684c1d3f380256735005750fb/0a8f8fa3eddd8a4b8025697700505ead?OpenDocument
http://213.38.88.195/coi/coipress.nsf/70e1fa6684c1d3f380256735005750fb/80c7e476e82c542680256977003adf9e?OpenDocument
kind regards,
Terry S. Singeltary Sr., Bacliff, Texas USA
"Terry S. Singeltary Sr." wrote:
>
> ######### Bovine Spongiform Encephalopathy
>
> Greetings again list members,
>
> Has anyone heard of any further development of the Schmerr test???
> I knew of powers within, that were trying to inhibit the progress
> of this testing (from a _most_ reliable source), but did not think they
> actually would stop the research.
>
> hmmmm, who knows???
>
> Here are a few links some may find informative;
>
> Opinion On
> Update of the Opinion given by the Scientific Committee on Medicinal
> Products and Medical Devices on The Risk Quantification For CJD
> Transmission Via Substances of Human Origin;
>
> 2. Screening assays
>
> It is assumed that although there is no proven or even probable case of
> transmission by blood or blood products the identification and exclusion
> of donors in the preclinical phase of CJD or vCJD would contribute to an
> increase in the safety margin and, probably, an increase in the
> confidence in blood and blood products by potential recipients.
> Therefore, the SCMPMD in its Opinion of October 1998 emphasised the need
> for "the development of a simple readily available ex vivo diagnostic
> test for preclinical nvCJD/CJD". In addition it stated: "When a
> validated test for TSE infectivity in donor blood becomes available, it
> should be implemented in routine donor screening as soon as possible and
> donors found to be positive should be excluded from donation. Member
> Statos should, in the interest of public health, warrant availability of
> TSE tests for blood screening in collaboration with possible patent
> holders."
>
> During the "WHO Consultation on Diagnostic Procedures for Transmissible
> Spongiform Encephalopathies: Need for Reference Reagents and Reference
> Panels" held in Geneva on March 22 and 23, 1999, M.J. Schmerr presented
> results of a new assay that may be able to detect the pathological fbrm
> of ption protein in blood of animals in the clinical as well as in the
> preclinical phase of TSE (serapie in sheep and chronic wasting disease
> in deer, Schmerr 1999, Schmerr et al. 1999). The basic reaction is the
> competition of the proteinase K treated sample with a labelled peptide
> derived from the sequence of prion protein binding to an antibody mised
> against this peptide (Schmerr et al. 1998). The test material is
> extracted from buff), coat prepreed from a sample of peripheral blood.
> >From the relation between ti'ee and bound peptide as determined by
> capillary electropheresis the amount of corn?ting protein i.e. protease
> resistant prion protein, is calculated.
>
> In contrast to other tests used for the detection of TSE infected
> animals or lbr confirmation of CJD/vCJD in humans the assay proposed by
> Schmerr uses for the first time as test material a body fluid, namely
> blood, which is eaqily availahl,~ In thi~ respect, this assay fulfils a
> prerequisite for a screening assay which could be used in the blood
> donation setting. However, it has to be stressed that this assay is far
> from ir~ing vaildated tidier in animals or in humans. On the contrary,
> preliminary tests with haman material performed in several laboratories
> have not yet validated this test.
>
> There is no doubt that the assay has the potential to be developed into
> a screening assay, but this developmere will need a number of carefully
> designed studies. Use in donor screening will not be possible until
> there is more information on the sensitivity, specificity and validity
> of the assay.
>
> The SCMPMD repeats its recommendation to support efforts in the
> development of easily applicable screening tests for CJD/vCJD.
>
> The SCMPMD would also like to draw the attention to an ethical aspect of
> the expected introduction of a screening assay for CJD/vCJD. The
> information of a positive test result would confront the individual with
> the diagnosis of an inevitably fatal disease without any reliable
> prediction of the duration of the preclinical phase. Such information
> could cause severe psychological stress and would demand careful
> counselling. In such a situation, it would not be surprising if donors
> would stop donating il' such a test for CJD/vCJD were introduced. If the
> number of those dollors is high the introduction of a screening assay
> would lead to a significant loss of donors who would have to be replaced
> by first time donors who are at higher risk of well known blood borne
> infections. This situation should be considered well in advance.
>
> 3. Exclusion of donors at risk for TSE infection by ruminant derived
> material
>
> Until the end of 1998 vCJD cases were observed only in the United
> Kingdom (UK), with one single exception. Therefore, residency in UK was
> described as one of the known risk factors for vCJD (the others being
> young age (i.e. below 53 years) and homozygosity of methionine at codon
> 129 of the prion protein gene). The exclusion of donors who resided for
> some time in the UK could, therefore, be considered as contributing to
> minimising the theoretical risk of vCJD transmission by blood and blood
> products.
>
> The first recommendation of this kind was given by the Ottawa based
> Bayer Advisory Council on Bioethics which stated in his working paper
> "Creutzfeldt-Jakob disease, blood and blood products: A bioethics
> framework" (1998):
> "The differences between classical CJD on the one hand and nvCJD on the
> other creme differences in the quality of the hypothetical risk. As
> discussed earlier, the new variant form appears to have crossed the
> species barrier from cattle. It has an earlier age at onset, and the los
> of pathological ptiohs is much greater than in classical forms of the
> disease. The anatomical distribution of nvCJD infectivity is also
> different, which raises the plausible possibility that it is more likely
> to have infectivity in the blood. Therefore, nvCJD is the wild card that
> warrants special vigilance. The disease appears to be isolated, at
> present, to parts of Europe. The number of people in affected countries
> who are currently incubating the disease is ankhown. The Council
> therefore recommends:
>
> 20. That persons who, at any time since 1980, have resided in a
> geographic area with a significant incidence of BSE or nvCJD not be
> permitted to contraute blood or plasma until the hypothetical risk of
> accepting donations from such persons can be evaluated."
>
> http://europa.eu.int/comm/food/fs/sc/scmp/out28_en.pdf
>
> also, for those interested, here are more documents on this and
> other issues;
>
> http://europa.eu.int/comm/food/fs/sc/scmp/out12_en.pdf
> http://europa.eu.int/comm/food/fs/sc/scmp/out20_en.html
> http://europa.eu.int/comm/food/fs/sc/scmp/out25_en.html
> http://europa.eu.int/comm/food/fs/sc/scmp/out29_en.pdf
>
> kind regards,
> Terry S. Singeltary Sr., Bacliff, Texas USA
2011
According to advisers to the British government, though the test is undoubtedly a significant step towards eliminating the incurable disease and preventing it from becoming endemic in society, it could result in a reduction in the number of blood donors and there are also fears it could increase insurance premiums.
Experts suspect that donors will be
reluctant to give blood if they risk being told that they have the possibility
of developing the disease which causes a horrible and agonising
death.
Dr. John Forsythe, chair of the Advisory Committee on the Safety of
Blood Tissues and Organs (SABTO) and a transplant surgeon at the Royal Infirmary
of Edinburgh says the test does have significant downsides, despite concerns
that the disease could become widespread in the UK.
http://vcjdblood.blogspot.com/2008/11/sabto-summary-of-1st-public-meeting.html
TSS
